

# Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

## Ri-1

RRID:CVCL\_1885

Type: Cell Line

### Proper Citation

RRID:CVCL\_1885

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1885](https://web.expasy.org/cellosaurus/CVCL_1885)

**Proper Citation:** RRID:CVCL\_1885

**Description:** Cell line Ri-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Diffuse large B-cell lymphoma activated B-cell type

**Defining Citation:** [PMID:2985879](#), [PMID:3098690](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:8558920](#), [PMID:9510473](#), [PMID:16960149](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31395879](#)

**Comments:** Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, lymphocytic type., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** Ri-1

**Synonyms:** RI-1, RI1, RIVA, Riva

**Cross References:** CLO:CLO\_0008814, EFO:EFO\_0006477, CLDB:cl5090, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03472482, BioSample:SAMN10988505,

cancercelllines:CVCL\_1885, Cell\_Model\_Passport:SIDM01858, Cosmic:919144, Cosmic:1086342, Cosmic:1517635, Cosmic:2297018, Cosmic:2437312, DepMap:ACH-000398, DSMZ:ACC-585, DSMZCellDive:ACC-585, ECACC:96090512, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM119557, GEO:GSM887539, GEO:GSM888622, GEO:GSM907521, GEO:GSM1035305, GEO:GSM1374849, IARC\_TP53:28266, LiGeA:CCLE\_317, Pharmacodb:RI1\_1314\_2019, Progenetix:CVCL\_1885, Wikidata:Q54950442

**ID:** CVCL\_1885

**Record Creation Time:** 20220427T221459+0000

**Record Last Update:** 20260905T182217+0000

---

## Ratings and Alerts

No rating or validation information has been found for Ri-1.

No alerts have been found for Ri-1.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 15 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. Cancer research.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer cell.

Phelan JD, et al. (2024) Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer cell, 42(2), 238.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Molecular cancer therapeutics, 23(3), 316.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. *Cancer research communications*, 4(5), 1328.

Zhuang X, et al. (2024) Functional genomics identifies N-acetylglucosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells. *Cell reports*, 43(4), 114105.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Kreer C, et al. (2023) Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals. *Nature communications*, 14(1), 7137.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.